Jonathan T Sims1, Rina Plattner. 1. Department of Molecular and Biomedical Pharmacology, University of Kentucky School of Medicine, Lexington, KY 40536, USA.
Abstract
PURPOSE: This study will determine whether MTT assays accurately assess the effect of STI571 (Gleevec; Abl kinase inhibitor) on the viability of cancer cells containing highly active Abl kinases. METHODS: Growth kinetics, tritiated thymidine, fluorescent caspase, MTT, and Cell Titer Glo (CTG) assays were used to determine the effect of STI571 on growth, proliferation, apoptosis, and viability of melanoma and breast cancer cells. RESULTS: STI571 inhibited growth and proliferation, and increased apoptosis. However, MTT assays indicated that STI571 increased cell viability. In contrast, STI571 induced a dose-dependent decrease in viability using CTG assays. CONCLUSIONS: Doses of STI571 (1-10 microM) required to inhibit endogenous Abl kinases interfere with the MTT assay, and therefore MTT cannot be used to determine the effect of STI571 on viability using these doses. Additionally, caution should be utilized when interpreting the results of MTT assays used to screen kinase inhibitors for anti-cancer activity, as drug effectiveness may be minimized.
PURPOSE: This study will determine whether MTT assays accurately assess the effect of STI571 (Gleevec; Abl kinase inhibitor) on the viability of cancer cells containing highly active Abl kinases. METHODS: Growth kinetics, tritiated thymidine, fluorescent caspase, MTT, and Cell Titer Glo (CTG) assays were used to determine the effect of STI571 on growth, proliferation, apoptosis, and viability of melanoma and breast cancer cells. RESULTS:STI571 inhibited growth and proliferation, and increased apoptosis. However, MTT assays indicated that STI571 increased cell viability. In contrast, STI571 induced a dose-dependent decrease in viability using CTG assays. CONCLUSIONS: Doses of STI571 (1-10 microM) required to inhibit endogenous Abl kinases interfere with the MTT assay, and therefore MTT cannot be used to determine the effect of STI571 on viability using these doses. Additionally, caution should be utilized when interpreting the results of MTT assays used to screen kinase inhibitors for anti-cancer activity, as drug effectiveness may be minimized.
Authors: Maritza E Mayorga; Daniel Sanchis; Ana M Perez de Santos; Ana Velasco; Xavier Dolcet; Josep M Casanova; Manel Baradad; Ramon Egido; Judith Pallares; Noemi Espurz; Daniel Benitez; Jordi Mila; Josep Malvehy; Teresa Castel; Joan X Comella; Xavier Matias-Guiu; Ramon Vilella; Rosa M Marti Journal: Melanoma Res Date: 2006-04 Impact factor: 3.599
Authors: M C Pagliacci; F Spinozzi; G Migliorati; G Fumi; M Smacchia; F Grignani; C Riccardi; I Nicoletti Journal: Eur J Cancer Date: 1993 Impact factor: 9.162
Authors: B J Druker; S Tamura; E Buchdunger; S Ohno; G M Segal; S Fanning; J Zimmermann; N B Lydon Journal: Nat Med Date: 1996-05 Impact factor: 53.440
Authors: Jessica M Posimo; Ajay S Unnithan; Amanda M Gleixner; Hailey J Choi; Yiran Jiang; Sree H Pulugulla; Rehana K Leak Journal: J Vis Exp Date: 2014-01-20 Impact factor: 1.355
Authors: Deep Jyoti Bhuyan; Jennette Sakoff; Danielle R Bond; Melanie Predebon; Quan V Vuong; Anita C Chalmers; Ian A van Altena; Michael C Bowyer; Christopher J Scarlett Journal: In Vitro Cell Dev Biol Anim Date: 2017-04-27 Impact factor: 2.416